ERBB2 and breast carcinoma: Future efforts should look to validate the high PPV of ERBB2 CNG by NGS for HER2-positive IHC/FISH in breast cancer and other tumor types and subsequently whether ERBB2 CNG is predictive of benefit from HER2-targeted therapy.